AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17061974 — intervention group
Group type: COMPARATOR
Intervention: No information from the fertility monitor (control group)
Number of subjects: 1453
Study 17061974 — intervention group
Group type: EXPERIMENTAL
Intervention: Late Fertile Time group
Number of subjects: 1453
Study 10578975 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-based assay to detect HSV-1 and HSV-2 in ThinPrep fixative
Number of subjects: 5
Study 8767242 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (HAL)
Number of subjects: 36
Study 8767242 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (ENF)
Number of subjects: 36
Study 8767242 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO)
Number of subjects: 36
Study 1662585 — intervention group
Group type: EXPERIMENTAL
Intervention: low-alcohol beer
Number of subjects: 72
Study 1662585 — intervention group
Group type: COMPARATOR
Intervention: usual drinking habits
Number of subjects: 72
Study 1662585 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma fatty acid concentrations
Number of subjects: 72
Study 1662585 — intervention group
Group type: EXPERIMENTAL
Intervention: logistic regression indices combining plasma apolipoprotein A‐II and linoleic acid concentrations
Number of subjects: 72
Study 7060825 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 12 mg/kg/day
Number of subjects: 71
Study 7060825 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 8 mg/kg/day
Number of subjects: 71
Study 7060825 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 4 mg/kg/day
Number of subjects: 71
Study 7060825 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 71
Study 30883056 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial envelope
Number of subjects: 6983
Study 30883056 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care strategies (Control)
Number of subjects: 6983
Study 29419437 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus bendamustine
Number of subjects: 357
Study 29419437 — intervention group
Group type: COMPARATOR
Intervention: Rituximab plus chlorambucil
Number of subjects: 357
Study 26718894 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minute Active Lesson Break
Number of subjects: 58
Study 26718894 — intervention group
Group type: COMPARATOR
Intervention: 10 minute Passive Lesson Break (reading)
Number of subjects: 58
Study 24603054 — intervention group
Group type: EXPERIMENTAL
Intervention: FemoSeal vascular closure device (VCD)
Number of subjects: 1001
Study 24603054 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (MC)
Number of subjects: 1001
Study 22307572 — intervention group
Group type: EXPERIMENTAL
Intervention: Men in 2008 with lower serum free testosterone compared to men in 1995
Number of subjects: 2400
Study 22307572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) in women in 2008
Number of subjects: 2400
Study 22307572 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture incidence in postmenopausal women in 2008
Number of subjects: 2400
Study 22307572 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral crush fractures in women
Number of subjects: 2400
Study 22307572 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholesterol and triglycerides
Number of subjects: 2400
Study 20973712 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (flexibly dosed 2-15 mg/day)
Number of subjects: 316
Study 20973712 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (fixed dose 5, 10, or 15 mg/day)
Number of subjects: 316
Study 20973712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flexibly dosed)
Number of subjects: 316
Study 20973712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fixed dose)
Number of subjects: 316
Study 20973712 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (both dosing regimens)
Number of subjects: 316
Study 17052252 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (standard tablet)
Number of subjects: 0
Study 17052252 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS (controlled release formulation)
Number of subjects: 0
Study 17052252 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin, Tamsulosin, Terazosin, Prazosin (α1-receptor antagonists)
Number of subjects: 0
Study 16230074 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg daily
Number of subjects: 182
Study 16230074 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg daily
Number of subjects: 182
Study 16230074 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg daily
Number of subjects: 182
Study 16230074 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.1 mg daily
Number of subjects: 182
Study 12123333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular depot medroxyprogesterone acetate (MPA) 500 mg on days 1, 14, and 28
Number of subjects: 71
Study 12123333 — intervention group
Group type: COMPARATOR
Intervention: Oral megestrol acetate 40 mg daily for 6 weeks
Number of subjects: 71
Study 9498941 — intervention group
Group type: EXPERIMENTAL
Intervention: Proventil HFA
Number of subjects: 0
Study 9498941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventolin
Number of subjects: 0
Study 9498941 — intervention group
Group type: COMPARATOR
Intervention: HFA‐134a placebo
Number of subjects: 0
Study 7836079 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiotherapy 60 Gy in 30 fractions in 3 weeks (arm II)
Number of subjects: 100
Study 7836079 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy 60 Gy in 30 fractions in 6 weeks (arm I)
Number of subjects: 100
Study 7836079 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy 60 Gy in 30 fractions in 6 weeks plus carboplatin 350 mg/m2 during weeks 1 and 5 (arm III)
Number of subjects: 100
Study 7836079 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy 60 Gy in 30 fractions in 3 weeks plus carboplatin 350 mg/m2 during week 1 (arm IV)
Number of subjects: 100
Study 7836079 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 100
Study 7836079 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy
Number of subjects: 100
Study 2136775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium bromide plus 4‐hourly fenoterol (group I, 50 patients)
Number of subjects: 145
Study 2136775 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐hourly fenoterol (group II, 50 patients)
Number of subjects: 145
Study 2136775 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐hourly fenoterol (group III, 45 patients)
Number of subjects: 145
Study 30787234 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post-pyloric feeding (EPF)
Number of subjects: 13
Study 30787234 — intervention group
Group type: COMPARATOR
Intervention: Delayed post-pyloric feeding (DPF)
Number of subjects: 13
Study 28391910 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy diet
Number of subjects: 173
Study 28391910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsoy plant diet
Number of subjects: 173
Study 28391910 — intervention group
Group type: COMPARATOR
Intervention: Dairy diet
Number of subjects: 173
Study 28391910 — intervention group
Group type: COMPARATOR
Intervention: Animal diet
Number of subjects: 173
Study 26389597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus memory support (CT + MS; n = 22)
Number of subjects: 42
Study 26389597 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy as-usual (CT-as-usual; n = 20)
Number of subjects: 42
Study 26389597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus memory support (CT + MS)
Number of subjects: 42
Study 26389597 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy as-usual (CT-as-usual)
Number of subjects: 42
Study 24406614 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine transdermal patch, dosage and duration not specified
Number of subjects: 0
Study 23031065 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prescription (individually tailored home-based exercise prescriptions for 6 months)
Number of subjects: 83
Study 23031065 — intervention group
Group type: COMPARATOR
Intervention: Baseline physical activity levels
Number of subjects: 83
Study 20826257 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg/d; TEL, n = 25)
Number of subjects: 49
Study 20826257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA, n = 24)
Number of subjects: 49
Study 17519582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato extract (TE) 360 mg per day for 8 weeks
Number of subjects: 33
Study 17519582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 15674509 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and propofol TCI (group FP)
Number of subjects: 75
Study 15674509 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and less than 1% sevoflurane (group Fs)
Number of subjects: 75
Study 15674509 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (group S)
Number of subjects: 75
Study 15674509 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between group FP and group Fs
Number of subjects: 75
Study 11880015 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative platelet plasmapheresis (APP group)
Number of subjects: 0
Study 11880015 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10434817 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural fentanyl (PCEF)
Number of subjects: 84
Study 10434817 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled i.v. morphine (PCIM)
Number of subjects: 84
Study 7877647 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 247
Study 7877647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy plus radiation
Number of subjects: 247
Study 1977703 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists (cimetidine, ranitidine, famotidine, nizatidine)
Number of subjects: 60
Study 1977703 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (omeprazole)
Number of subjects: 60
Study 1977703 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 60
Study 1977703 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes
Number of subjects: 60
Study 82356 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g of oral zinc sulphate daily
Number of subjects: 54
Study 82356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31846745 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 68
Study 31846745 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bandaging
Number of subjects: 68
Study 31846745 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (taping and elastic bandaging)
Number of subjects: 68
Study 30525306 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic standardized nursing care plans (SNCPs)
Number of subjects: 0
Study 30525306 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based standardized nursing care plans (SNCPs)
Number of subjects: 0
Study 28425966 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-Fructose (GF)
Number of subjects: 16
Study 28425966 — intervention group
Group type: COMPARATOR
Intervention: Water (C)
Number of subjects: 16
Study 24918475 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mL oral 24% sucrose (n=29)
Number of subjects: 56
Study 24918475 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (n=27)
Number of subjects: 56
Study 23537606 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Crisis Plans (JCPs)
Number of subjects: 569
Study 23537606 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 569
Study 21665899 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1.5 MAC
Number of subjects: 71
Study 21665899 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.5 MAC
Number of subjects: 71
Study 21665899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.5 MAC
Number of subjects: 71
Study 21665899 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1 MAC
Number of subjects: 71
Study 21665899 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1 MAC
Number of subjects: 71
Study 21665899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1 MAC
Number of subjects: 71
Study 19192993 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-day famciclovir (1 g twice-daily)
Number of subjects: 1179
Study 19192993 — intervention group
Group type: COMPARATOR
Intervention: 3-day valacyclovir (500 mg twice-daily)
Number of subjects: 1179
Study 19192993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1179
Study 17196793 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1g/day
Number of subjects: 0
Study 17196793 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 2g/day
Number of subjects: 0
Study 17196793 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 3g/day
Number of subjects: 0
Study 17196793 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 4g/day
Number of subjects: 0
Study 17196793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14716727 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds Ratio (OR)
Number of subjects: 0
Study 14716727 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic (ROC) methods
Number of subjects: 0
Study 14716727 — intervention group
Group type: COMPARATOR
Intervention: Success rates in treatment and control groups
Number of subjects: 0
Study 14716727 — intervention group
Group type: COMPARATOR
Intervention: Number needed to treat (NNT)
Number of subjects: 0
Study 14716727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass kappa
Number of subjects: 0
Study 14716727 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted kappa
Number of subjects: 0
Study 11471927 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg once daily in the evening (n = 15)
Number of subjects: 22
Study 11471927 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 22
Study 9035016 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac 150 mg bid
Number of subjects: 1446
Study 9035016 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac 500 mg bid
Number of subjects: 1446
Study 9035016 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen 600 mg qid
Number of subjects: 1446
Study 7942046 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I fibre proportion (type I%) in women and men
Number of subjects: 83
Study 7942046 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (VO2max)
Number of subjects: 83
Study 7942046 — intervention group
Group type: EXPERIMENTAL
Intervention: Running performance (9 min endurance test)
Number of subjects: 83
Study 7942046 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength tests (Sargent jump, handgrip test, two-hand lift)
Number of subjects: 83
Study 7942046 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity index from questionnaire
Number of subjects: 83
Study 3428339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium Bromide (OTB)
Number of subjects: 10
Study 3428339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31610100 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tramadol 50 mg
Number of subjects: 0
Study 31610100 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tramadol 75 mg
Number of subjects: 0
Study 31610100 — intervention group
Group type: COMPARATOR
Intervention: Oral tramadol 100 mg
Number of subjects: 0
Study 29358423 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based perioperative care programme
Number of subjects: 433
Study 29358423 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 433
Study 28583289 — intervention group
Group type: EXPERIMENTAL
Intervention: ATLG
Number of subjects: 202
Study 28583289 — intervention group
Group type: COMPARATOR
Intervention: non-ATLG
Number of subjects: 202
Study 26645271 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate binder therapy taken with meals
Number of subjects: 60
Study 26645271 — intervention group
Group type: COMPARATOR
Intervention: Standard prescription of phosphate binders
Number of subjects: 60
Study 24146510 — intervention group
Group type: EXPERIMENTAL
Intervention: General acteoside of Rehmanniae leaves (two 200mg tablets, bid)
Number of subjects: 400
Study 24146510 — intervention group
Group type: COMPARATOR
Intervention: Piperazine ferulate (four 50-mg tablets, bid)
Number of subjects: 400
Study 24146510 — intervention group
Group type: EXPERIMENTAL
Intervention: General acteoside of Rehmanniae leaves
Number of subjects: 400
Study 24146510 — intervention group
Group type: COMPARATOR
Intervention: Piperazine ferulate
Number of subjects: 400
Study 21348543 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UVB treatment in vitiligo-melasma group
Number of subjects: 0
Study 21348543 — intervention group
Group type: COMPARATOR
Intervention: Narrow-band UVB treatment in vitiligo group
Number of subjects: 0
Study 18364505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HT)
Number of subjects: 442
Study 18364505 — intervention group
Group type: COMPARATOR
Intervention: Best management without hormones (Control)
Number of subjects: 442
Study 18364505 — intervention group
Group type: EXPERIMENTAL
Intervention: HT
Number of subjects: 442
Study 18364505 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 442
Study 17166808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic balance training using commercially available balance training mechanical apparatus
Number of subjects: 16
Study 17166808 — intervention group
Group type: COMPARATOR
Intervention: Physically managed by a physiotherapist (Control)
Number of subjects: 16
Study 15117001 — intervention group
Group type: EXPERIMENTAL
Intervention: Font presented with 1 word during study
Number of subjects: 0
Study 15117001 — intervention group
Group type: EXPERIMENTAL
Intervention: Font presented with 20 words during study
Number of subjects: 0
Study 15117001 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency fonts
Number of subjects: 0
Study 11351939 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 30
Study 11351939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9429329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatation
Number of subjects: 210
Study 9429329 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Urethrotomy
Number of subjects: 210
Study 9429329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 210
Study 8105717 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (4 micrograms/kg body weight)
Number of subjects: 100
Study 8105717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8105717 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1 mg/kg propofol)
Number of subjects: 100
Study 8105717 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 mg/kg propofol)
Number of subjects: 100
Study 8105717 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2 mg/kg propofol)
Number of subjects: 100
Study 8105717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mg/kg propofol)
Number of subjects: 100
Study 8105717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.5 mg/kg propofol)
Number of subjects: 100
Study 8105717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mg/kg propofol)
Number of subjects: 100
Study 3305087 — intervention group
Group type: EXPERIMENTAL
Intervention: Gossypol
Number of subjects: 0
Study 3305087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29315132 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help cognitive behavior therapy (SH-CBT)
Number of subjects: 124
Study 29315132 — intervention group
Group type: COMPARATOR
Intervention: No treatment waitlist control (NTWC)
Number of subjects: 124
Study 27050189 — intervention group
Group type: EXPERIMENTAL
Intervention: IV metoprolol (2 × 5-mg bolus)
Number of subjects: 683
Study 27050189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 683
Study 24988513 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education with telephone follow-up on wound care and clean dressing technique at home.
Number of subjects: 126
Study 24988513 — intervention group
Group type: COMPARATOR
Intervention: Normal wound care (sterile dressing changes by professional nurses in a nonspecialized outpatient clinic).
Number of subjects: 126
Study 22280501 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole systems model of self-management support
Number of subjects: 0
Study 22280501 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20862941 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 60
Study 20862941 — intervention group
Group type: COMPARATOR
Intervention: Hot compress
Number of subjects: 60
Study 20862941 — intervention group
Group type: COMPARATOR
Intervention: Infrared irradiation
Number of subjects: 60
Study 18420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 4 mg every 2 weeks
Number of subjects: 40
Study 18420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg every 2 weeks
Number of subjects: 40
Study 18420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg every 4 weeks
Number of subjects: 40
Study 18420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 12 mg every 4 weeks
Number of subjects: 40
Study 16105815 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg(‐1) iv
Number of subjects: 40
Study 16105815 — intervention group
Group type: COMPARATOR
Intervention: Thiopental 5 mg.kg(‐1) iv
Number of subjects: 40
Study 14520853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined psychocorrection including neuroleptic trifluoperasine and psychorelaxation therapy
Number of subjects: 132
Study 10588623 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation
Number of subjects: 200